MedTrace Logo

Continuous Glucose Monitoring With a Subcutaneous Sensor During Critical Illness and Surgery

NCT00694473 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2018-03-08

Study results available
· View outcomes & findings →

Summary

We hypothesize that measurements of interstitial fluid (ISF) glucose by the FreeStyle Navigator (Abbot Diabetes Care), a continuous glucose monitoring system, will correlate with blood glucose (BG) values in surgical and ICU patients with a clinically useful degree of accuracy.

Conditions

  • Critical Illness

Interventions

DEVICE

Freestyle Navigator

Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU

Sponsors & Collaborators

  • Abbott Diabetes Care

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Steven J. Russell, M.D., Ph.D. · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00694473 on ClinicalTrials.gov